C4 Therapeutics Shares Rise 19% on Bristol Myers Positive Data
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 21 hours ago
0mins
Shares of C4 Therapeutics (CCCC) are up 19%, or 70c, to $4.36 in midday trading after Bristol Myers (BMY) announced positive Phase 3 multiple myeloma data.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CCCC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CCCC
About CCCC
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on delivering targeted protein degradation science to create a new generation of medicines that transform patients’ lives. The Company is focused on progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to design and optimize small-molecule medicines to address difficult-to-treat diseases. Its advanced product candidate, cemsidomide, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3. Cemsidomide is in clinical development for multiple myeloma (MM), and non-Hodgkin lymphoma (NHL). Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. It is also developing CFT8919, an orally bioavailable, allosteric, mutant-selective BiDAC degrader of epidermal growth factor receptor (EGFR), with an L858R mutation in non-small lung cancer (NSCLC).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
C4 Therapeutics Hits 52-Week High Following BMY's Positive Myeloma Trial Results
- Impressive Survival Data: Bristol-Myers Squibb's (BMY) late-stage SUCCESSOR-2 trial for its multiple myeloma candidate mezigdomide demonstrated over a 50% improvement in cancer-free survival, positively impacting C4 Therapeutics (CCCC) stock performance.
- Strong Market Reaction: Following BMY's announcement, C4 Therapeutics' stock surged to a 52-week high, indicating increased investor confidence in its lead candidate cemsidomide, particularly given the similarities in treatment strategies.
- Future Data Sharing Plans: C4 plans to present data from a Phase 1b trial evaluating cemsidomide in combination with approved multiple myeloma therapies in H2 2026, which will further support its market prospects.
- Analyst Optimism: Jefferies analyst Akash Tewari expressed a positive outlook for C4, suggesting that BMY's favorable data will have a beneficial read-through for C4, maintaining a Buy rating on the stock, reflecting market recognition of its growth potential.
See More
C4 Therapeutics Q1 Earnings Beat Expectations with Revenue of $6.15M
- Earnings Highlights: C4 Therapeutics reported a Q1 GAAP EPS of -$0.20, beating expectations by $0.06, indicating potential improvements in profitability.
- Revenue Performance: The company generated $6.15M in revenue for Q1, a 15.1% year-over-year decline, yet it surpassed market expectations by $1.73M, demonstrating resilience in a challenging market.
- Cash Flow Status: As of March 31, 2026, C4's cash, cash equivalents, and marketable securities totaled $268.3M, down from $297.1M as of December 31, 2025, primarily due to operational cash usage, highlighting challenges in cash management.
- Funding Outlook: C4 Therapeutics expects its current cash and equivalents to fund operations until the end of 2028, showcasing strategic foresight in financial planning despite revenue pressures.
See More
C4 Therapeutics Partners with Roche to Develop Novel Cancer Drugs
- New Drug Collaboration: C4 Therapeutics (CCCC) has announced a new partnership with long-time collaborator Roche (RHHBY) to develop a novel class of cancer drugs known as degrader-antibody conjugates (DACs), combining antibody-drug conjugation (ADC) with targeted protein degradation (TPD) to advance two DAC programs against undisclosed oncology targets.
- Funding and Milestones: Under the agreement, C4 is eligible to receive $20 million from Roche for the two programs, with additional payments if Roche opts for a third program, alongside potential milestone payments exceeding $1 billion, contingent on achieving specific R&D, regulatory, and commercial targets.
- Long-term Partnership: Since signing a licensing deal in 2016, C4 Therapeutics and Roche have collaborated for a decade in targeted protein degradation research, with CEO Andrew Hirsch noting that this partnership has established a new modality for cancer treatment.
- Market Potential and Strategic Importance: This collaboration not only highlights C4's innovative capabilities in cancer drug development but also has the potential to significantly enhance the company's competitiveness and market share in the biopharmaceutical sector through the successful development of new drugs.
See More
C4 Therapeutics Expands Partnership with Roche for Cancer Treatments
- Stock Surge: C4 Therapeutics shares rose 5% in pre-market trading on Thursday, reflecting positive market sentiment regarding the company's expanded collaboration with Swiss pharmaceutical giant Roche, indicating investor confidence in future cancer treatment developments.
- Collaboration Focus: The partnership will concentrate on developing emerging cancer therapies using degrader-antibody conjugates (DAC) and targeted protein degradation (TPD) processes, highlighting the company's strategic positioning in innovative drug development.
- Financial Gains: Under the agreement, C4 Therapeutics will receive a $20 million upfront payment and has the potential to earn over $1 billion in milestone payments, along with tiered royalties on future sales, significantly enhancing the company's financial stability.
- Market Potential: The collaboration aims to develop DAC therapies targeting undisclosed cancer indications, underscoring the company's potential impact in the cancer treatment market and future growth opportunities.
See More
C4 Therapeutics Partners with Roche for DAC Development
- Collaboration Agreement: C4 Therapeutics has entered into a new collaboration with Roche to advance research in degrader-antibody conjugates (DACs), focusing on developing DACs against undisclosed oncology targets, highlighting strategic synergy in cancer treatment.
- Financial Support: C4 will receive a $20 million upfront payment and is eligible for over $1 billion in discovery, regulatory, and commercial milestone payments, significantly enhancing the company's financial stability and R&D capabilities.
- Technology Platform Utilization: C4 will leverage its TORPEDO platform to design degrader payload candidates, while Roche will select and design the antibody, showcasing complementary strengths that could accelerate drug development timelines.
- Positive Market Reaction: In pre-market trading on Nasdaq, C4 shares rose 2.44% to $2.97, reflecting market optimism regarding the collaboration's prospects, which may drive future stock performance.
See More
C4 Therapeutics Enhances Ongoing Partnership with Roche via New Collaboration to Explore and Develop Degrader-Antibody Conjugates (DACs)
- Partnership Expansion: Therapeutics has expanded its long-term partnership with Roche through a new collaboration agreement.
- Research Focus: The collaboration will focus on discovering and developing degrader-antibody conjugates (DACs).
See More
C4 Therapeutics Hits 52-Week High Following BMY's Positive Myeloma Trial Results
- Impressive Survival Data: Bristol-Myers Squibb's (BMY) late-stage SUCCESSOR-2 trial for its multiple myeloma candidate mezigdomide demonstrated over a 50% improvement in cancer-free survival, positively impacting C4 Therapeutics (CCCC) stock performance.
- Strong Market Reaction: Following BMY's announcement, C4 Therapeutics' stock surged to a 52-week high, indicating increased investor confidence in its lead candidate cemsidomide, particularly given the similarities in treatment strategies.
- Future Data Sharing Plans: C4 plans to present data from a Phase 1b trial evaluating cemsidomide in combination with approved multiple myeloma therapies in H2 2026, which will further support its market prospects.
- Analyst Optimism: Jefferies analyst Akash Tewari expressed a positive outlook for C4, suggesting that BMY's favorable data will have a beneficial read-through for C4, maintaining a Buy rating on the stock, reflecting market recognition of its growth potential.
See More
C4 Therapeutics Q1 Earnings Beat Expectations with Revenue of $6.15M
- Earnings Highlights: C4 Therapeutics reported a Q1 GAAP EPS of -$0.20, beating expectations by $0.06, indicating potential improvements in profitability.
- Revenue Performance: The company generated $6.15M in revenue for Q1, a 15.1% year-over-year decline, yet it surpassed market expectations by $1.73M, demonstrating resilience in a challenging market.
- Cash Flow Status: As of March 31, 2026, C4's cash, cash equivalents, and marketable securities totaled $268.3M, down from $297.1M as of December 31, 2025, primarily due to operational cash usage, highlighting challenges in cash management.
- Funding Outlook: C4 Therapeutics expects its current cash and equivalents to fund operations until the end of 2028, showcasing strategic foresight in financial planning despite revenue pressures.
See More
C4 Therapeutics Partners with Roche to Develop Novel Cancer Drugs
- New Drug Collaboration: C4 Therapeutics (CCCC) has announced a new partnership with long-time collaborator Roche (RHHBY) to develop a novel class of cancer drugs known as degrader-antibody conjugates (DACs), combining antibody-drug conjugation (ADC) with targeted protein degradation (TPD) to advance two DAC programs against undisclosed oncology targets.
- Funding and Milestones: Under the agreement, C4 is eligible to receive $20 million from Roche for the two programs, with additional payments if Roche opts for a third program, alongside potential milestone payments exceeding $1 billion, contingent on achieving specific R&D, regulatory, and commercial targets.
- Long-term Partnership: Since signing a licensing deal in 2016, C4 Therapeutics and Roche have collaborated for a decade in targeted protein degradation research, with CEO Andrew Hirsch noting that this partnership has established a new modality for cancer treatment.
- Market Potential and Strategic Importance: This collaboration not only highlights C4's innovative capabilities in cancer drug development but also has the potential to significantly enhance the company's competitiveness and market share in the biopharmaceutical sector through the successful development of new drugs.
See More
C4 Therapeutics Expands Partnership with Roche for Cancer Treatments
- Stock Surge: C4 Therapeutics shares rose 5% in pre-market trading on Thursday, reflecting positive market sentiment regarding the company's expanded collaboration with Swiss pharmaceutical giant Roche, indicating investor confidence in future cancer treatment developments.
- Collaboration Focus: The partnership will concentrate on developing emerging cancer therapies using degrader-antibody conjugates (DAC) and targeted protein degradation (TPD) processes, highlighting the company's strategic positioning in innovative drug development.
- Financial Gains: Under the agreement, C4 Therapeutics will receive a $20 million upfront payment and has the potential to earn over $1 billion in milestone payments, along with tiered royalties on future sales, significantly enhancing the company's financial stability.
- Market Potential: The collaboration aims to develop DAC therapies targeting undisclosed cancer indications, underscoring the company's potential impact in the cancer treatment market and future growth opportunities.
See More
C4 Therapeutics Partners with Roche for DAC Development
- Collaboration Agreement: C4 Therapeutics has entered into a new collaboration with Roche to advance research in degrader-antibody conjugates (DACs), focusing on developing DACs against undisclosed oncology targets, highlighting strategic synergy in cancer treatment.
- Financial Support: C4 will receive a $20 million upfront payment and is eligible for over $1 billion in discovery, regulatory, and commercial milestone payments, significantly enhancing the company's financial stability and R&D capabilities.
- Technology Platform Utilization: C4 will leverage its TORPEDO platform to design degrader payload candidates, while Roche will select and design the antibody, showcasing complementary strengths that could accelerate drug development timelines.
- Positive Market Reaction: In pre-market trading on Nasdaq, C4 shares rose 2.44% to $2.97, reflecting market optimism regarding the collaboration's prospects, which may drive future stock performance.
See More
C4 Therapeutics Enhances Ongoing Partnership with Roche via New Collaboration to Explore and Develop Degrader-Antibody Conjugates (DACs)
- Partnership Expansion: Therapeutics has expanded its long-term partnership with Roche through a new collaboration agreement.
- Research Focus: The collaboration will focus on discovering and developing degrader-antibody conjugates (DACs).
See More
